Mavoglurant

Mavoglurant occupies the allosteric transmembrane pocket of mGlu5 and reduces receptor signalling triggered by glutamate, damping the exaggerated group I metabotropic tone that characterizes several neurological disorders ^[1]. In Parkinson's disease, striatal mGlu5 is thought to amplify aberrant corticostriatal glutamate transmission that drives levodopa-induced dyskinesia; a 13-week randomized dose-finding study reported that 200 mg daily improved modified Abnormal Involuntary Movement Scale scores relative to placebo without degrading underlying antiparkinsonian efficacy ^[1]. A broader review of mGlu5 antagonists concluded that early proof-of-concept work with mavoglurant was encouraging but that two subsequent trials failed to confirm robust anti-dyskinetic efficacy, tempering enthusiasm for the approach ^[2].

The fragile X program rested on the mGluR theory of fragile X syndrome, in which loss of FMRP protein leaves mGlu5-driven protein synthesis unchecked at the synapse. Despite a compelling preclinical rationale, the large multi-site FXLEARN study found no significant effect of mavoglurant on language learning in young children with fragile X syndrome ^[3], and companion biomarker analyses showed no change in Akt/mTOR or matrix metalloproteinase-9 signalling that would indicate target engagement translating into benefit ^[4]. Together these results marked the end of mavoglurant's fragile X development while leaving its value as a selective research tool intact.

Moderate clinical evidence with predominantly negative pivotal outcomes

Across Parkinson's disease trials mavoglurant was generally tolerated, with the most common adverse events being dizziness, hallucinations, fatigue, nasopharyngitis, diarrhoea and insomnia occurring more often than with placebo. Neuropsychiatric effects, particularly dizziness and hallucination, reflect central mGlu5 modulation and warranted monitoring. Fragile X studies in children reported an acceptable tolerability profile at the doses tested. As an investigational agent it is not approved for any indication and should be regarded as research-only.

Mavoglurant was developed by Novartis as AFQ056 and entered clinical testing in the late 2000s, riding a wave of interest in mGlu5 as a target for Parkinson's disease dyskinesia, fragile X syndrome and other conditions. Positive early dyskinesia signals prompted expanded trials, and the fragile X hypothesis generated substantial academic and industry investment. After the FXLEARN language study and subsequent dyskinesia trials failed to demonstrate durable clinical benefit, active development wound down, leaving mavoglurant as a well-characterized probe compound.

Within neuropharmacology mavoglurant is regarded as one of the best-studied clinical-stage mGlu5 negative allosteric modulators and a landmark test of the mGluR theory of fragile X syndrome. Its mixed results are frequently cited as a cautionary example of strong preclinical rationale failing to translate, and it is often discussed alongside basimglurant and dipraglurant. In nootropic and biohacking circles it is known conceptually rather than used, given its investigational status and lack of availability.